Faecal microbiota transplantation for Clostridium difficile‐associated diarrhoea: a systematic review of randomised controlled trials

  title={Faecal microbiota transplantation for Clostridium difficile‐associated diarrhoea: a systematic review of randomised controlled trials},
  author={Paul Moayyedi and Yuhong Yuan and Harith Baharith and Alexander Charles Ford},
  journal={Medical Journal of Australia},
Objectives: Faecal microbiota transplantation (FMT) has emerged as a useful approach for treating Clostridium difficile‐associated diarrhoea (CDAD). Randomised controlled trials (RCTs) have recently evaluated its effectiveness, but systematic reviews have focused on evidence from case series. We therefore conducted a systematic review and meta‐analysis of RCTs evaluating the effectiveness of FMT for treating CDAD. 

Systematic review with meta‐analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome

Faecal microbiota transplantation is a highly effective treatment against recurrent Clostridioides difficile infection in randomised controlled trials (RCTs), and may be beneficial in ulcerative colitis, however, its efficacy in IBS is uncertain.

Fecal microbiota transplantation for recurrent Clostridium difficile infection

It is shown that fecal microbiota transplantation is 44%–96% effective in resolving recurrent C. difficile infection in patients with two or more recurrences, comparable or superior to conventional treatment with vancomycin taper and pulse.

Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis

FMT is a promising treatment modality for rCDI compared with MT alone and more well-designed RCTs directed at homogenous FMT preparation and delivery methods are required to validate these findings.

Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections

It is shown that it is likely that multiple factors contribute to the elimination of symptoms of C. difficile infections after fecal microbiota transplantation.

Is a Single Fecal Microbiota Transplant a Promising Treatment for Recurrent Clostridium difficile Infection?

Controversy in FMT methodologies and reporting within randomized controlled trials, all of which may influence clinical outcomes in treated patients are discussed and the question of whether single vs multiple FMTs are necessary to achieve favorable outcomes for the treatment of recurrent Clostridium difficile infection is focused on.

Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials

The findings of this study suggested no difference between single or multiple infusions of FMT and bezlotoxumab in reducing the risk of RCDI in hospitalised patients, however, FMT was associated with a higher rate of non-serious diarrhoea as opposed to SAT used alone or in combination with beZlotoxumsab.

This is a repository copy of Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome

The primary outcome is to define cure following duration of follow-up and proportion of female patients is to be controlled for.

Healthcare providers’ perception of faecal microbiota transplantation with clostridium difficile infection and inflammatory bowel disease: a quantitative systematic review

Healthcare providers’ knowledge of FMT is relatively low and education is an effective strategy to improve it, as knowledge ofFMT increases, willingness to recommend it also increases and further research is required to explore the donor screening procedure.

Are stool transplants effective for recurrent Clostridioides difficile colitis?

FMT seems to be a safe and effective treatment for patients with recurrent Clostridioides difficile infections that have failed oral antibiotic therapy, resulting in an increase in cure rates by up to 30% (SOR:B), but the most effective delivery method of FMT preparation is not clear.



Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection – fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy

Faecal microbiota transplantation (FMT) has become routine in managing recurrent C. difficile infection (CDI) refractory to antibiotics.

Faecal microbiota transplant for recurrent Clostridium difficile infection using long‐term frozen stool is effective: clinical efficacy and bacterial viability data

Faecal microbial transplant (FMT) for recurrent Clostridium difficile infection (rCDI) is greatly facilitated by frozen stool banks. However, the effect of frozen storage of stool for greater than 2

Fecal microbiota transplant in patients with Clostridium difficile infection: A systematic review

BACKGROUND Fecal microbiota transplantation (FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile infection (CDI). The

Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review.

FMT is highly effective in CDI, and holds promise in UC; as for CD, chronic constipation, pouchitis and IBS data are too limited to draw conclusions.

European consensus conference on faecal microbiota transplantation in clinical practice

This consensus report strongly recommends the implementation of FMT centres for the treatment of C. difficile infection as well as traces the guidelines of technicality, regulatory, administrative and laboratory requirements.

Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead

FMT as a therapeutic tool has evolved from the original format of blended donor stool and moved towards a refined product comprising a myriad of microbial components, presented aesthetically as encapsulated lyophilized powder.

Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection

A double-blind, randomized, controlled study of colonoscopic FMT for treatment of recurrent CDI, with results suggesting that colonoscopic delivery has advantages in terms of efficacy, safety, and patient acceptance and tolerability compared with administration via the nasoenteric route.

Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

Among adults with recurrent or refractory CDI, the use of frozen compared with fresh FMT did not result in worse proportion of clinical resolution of diarrhea, and its use is a reasonable option in this setting.

Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study.

  • I. YoungsterJ. Sauk E. Hohmann
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2014
In the initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI and NGT administration appears to be as effective as colonoscopy administration.

Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial

  • S. HotaV. Sales S. Poutanen
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2017
In patients experiencing an acute episode of recurrent CDI, a single FT by enema was not significantly different from oral vancomycin taper in reducing recurrentCDI, and further research is needed to explore optimal donor selection, FT preparation, route, timing, and number of administrations.